Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874597 | 0.88 | CFTR (0.51) | CFTRNOTUMSOS1KIF11MAPT | |
| SCHEMBL1763845 | 0.85 | CFTR (0.49) | CFTRNOTUMSOS1KDRGAA | |
| SCHEMBL27890 | 0.82 | KDM4E (0.43) | NOTUMMAPTPDGFRBFGFR1PDGFRA | |
| SCHEMBL22833380 | 0.82 | CFTR (0.66) | CFTRNOTUMSOS1MAPTKDM4E | |
| SCHEMBL27447768 | 0.82 | CFTR (0.47) | CFTRNOTUMSOS1MAPTKDR | |
| SCHEMBL8539026 | 0.82 | NOTUM (0.60) | CFTRNOTUMSOS1MAPTPDGFRB | |
| SCHEMBL7086639 | 0.82 | GAA (0.47) | CFTRNOTUMSOS1MAPTKDM4E | |
| SCHEMBL7079991 | 0.81 | RXRA (0.45) | NOTUMKIF11 | |
| SCHEMBL20470613 | 0.80 | PDGFRB (0.42) | NOTUMMAPTPDGFRBFGFR1PDGFRA | |
| SCHEMBL19491469 | 0.80 | CFTR (0.48) | CFTRNOTUMSOS1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1184196-C | Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | AVENTIS PHARMA GMBH (DE) | 2005-01-12 | — | — | CN | disclosed |
| US-6617344-B2 | Suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| CN-1373757-A | Heterocyclically substd, benzoylguanidine, method for production thereof, use thereof as medicament or means of diagnosis and medicaments contg. same | AVENTIS PHARMA GMBH (DE) | 2002-10-09 | — | — | CN | disclosed |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2002-07-25 | — | — | US | disclosed |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | CFTR 3411/4885NOTUM 2951/4885SOS1 1877/4885 |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | CFTR 3411/4885NOTUM 2951/4885SOS1 1877/4885 |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | CFTR 3411/4885NOTUM 2951/4885SOS1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.